Amgen bets on ChemoCentryx’s rare disease drug in $3.7 billion deal
Amgen has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.